Trials / Completed
CompletedNCT03138031
Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma
Outcome of Percutaneous Ethanol Alcohol Injection (PEI) for the Large and Unresectable Hepatocellular Carcinoma.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- The National Ribat University · Academic / Other
- Sex
- All
- Age
- 15 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.
Detailed description
Assessment of the overall (OS); one year; two years and three years' survival rates; the disease free survival (DFS) and the tumor response rate in the patients undergoing (PAT or PEI) for the large and inoperable hepatocellular carcinoma. This is a prospective non randomized trial carried out at the Ribat University Hospital between May 2017 to April 2020.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Percutaneous ethanol alcohol injection | Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of "8" limits the procedure. Post-procedure analgesia may be required. |
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-30
- First posted
- 2017-05-03
- Last updated
- 2019-05-14
Locations
1 site across 1 country: Sudan
Source: ClinicalTrials.gov record NCT03138031. Inclusion in this directory is not an endorsement.